Device Trial Radar · NCT06848400
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
482
Actual
Start
Apr 3, 2025
Primary completion
Feb 18, 2026
Study completion Feb 18, 2026
Sponsor
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangdong Provincial Hospital of Traditional Chinese Medicine; Second Affiliated Hospital of Guangzhou Medical University; ZhuHai Hospital; Pingshan People's Hospital; Ganzhou City People's Hospital; Wuxi People's Hospital; Prince of Wales Hospital, Shatin, Hong Kong; Longgang District People's Hospital of Shenzhen; Mianyang Central Hospital; Renhua People's Hospital
- First posted
- Feb 27, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the diagnostic accuracy of the AI-integrated Capsule Gastroscopy (ACG) system in simulated home-use conditions for detecting upper gastrointestinal (UGI) abnormalities. It will also compare the diagnostic accuracy and time efficiency of AI-assisted interpretation versus manual reading of ACG data. The main questions it aims to answer are: What is the diagnostic accuracy of the ACG system, using conventional esophagogastroduodenoscopy (EGD) as a standard of reference? Does AI-assisted ACG reading improve diagnostic accuracy or reduce reading time compared to manual ACG video reading? Researchers will compare ACG results to conventional EGD findings (standard of reference) to determine if ACG can serve as a reliable method for UGI disease detection in home scenarios. Participants will: Undergo an ACG examination in a simulated home environment. Complete an EGD procedure within 24 hours post-ACG ingestion.
Conditions
- Gastric Lesion
- Gastritis
- Upper Gastrointestinal Bleeding (UGIB)
- Gastric Dysplasia
- Gastric Ulcer
- Gastric Neoplasms
Interventions
AI-integrated Capsule Gastroscopy (ACG) examinationDevice
Product name: Gastric Capsule Endoscope System Specification model: GICE-1000 Manufacturer: Guangzhou Side Medical Technology Co., Ltd.
Electronic gastroduodenoscopy (EGD) examinationDevice
EGD was the reference standard against which ACG was compared, and it was performed within 24 hours post-ACG ingestion time. Product name: Electronic gastrointestinal endoscope (EGD) Specifications and models: GIF-290 series Manufacturer: Olympus, Tokyo, Japan
Primary outcomes
What the sponsor says the trial is designed to measure.
- Diagnostic accuracy of ACG in screening for common UGI abnormalitiesTime frame: Through study completion, an average of 1 year.
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Guangdong Provincial Hospital of Traditional Chinese Medicine
Guangzhou, Guangdong, China
Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
9 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.